Joseph Frattaroli, C.P.A.

Joseph Frattaroli, C.P.A.

Former Chief Financial OfficeratInhibikase Therapeutics· In proxies 2022–2024

Pay in FY2024-36% from the year before · Inhibikase Therapeutics stock +155.9% the same year

Joseph Frattaroli, C.P.A. was paid $370.4K in FY2024 (Dec), down 36%. Inhibikase Therapeutics stock rose 155.9% that year.

Pay$100 in the stock at the end of FY21 → $37
Pay is from the Summary Compensation Table of each Inhibikase Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Inhibikase TherapeuticsPublic company · 4 yr
    • Former Chief Financial Officer2022 – Present · 4 yrStock in role -83%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?